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Abstract 
 
Diabetes mellitus is a chronic disease that afflicts 347 million people worldwide. 
Type 2 diabetes (T2DM) accounts for approximately 90% of diabetes mellitus cases. 
Insulin insensitivity is a prominent physiological change in patients with T2DM. This 
is caused by decreased function or dysfunction of the insulin or IGF-1 receptor signaling 
pathway.  
Recent research has indicated that T2DM patients are at increased risk of 
developing neurodegenerative diseases. Brain shrinkage due to neural cell death is a 
common feature in neurodegenerative diseases and can be found in specific regions of 
the brain. Regulatory factors may increase or decrease the rate of neuronal cell death 
(apoptosis). Pre-optic regulatory factor-2 (Porf-2) is a protein that contains a RhoGAP 
domain; it has both anti-proliferative and pro-apoptotic properties in neural stem cells.  
The goal of this research project was to study potential links between 
insulin/IGF-1 signaling and Porf-2 expression. We did this by decreasing the levels of 
insulin receptor (IR). We hypothesized that when the insulin or IGF-1 downstream 
signaling pathway was reduced, Porf-2 expression would increase.  
Fischer’s Rat Thyroid cells (FRTL-5) were transfected with small-hairpin RNA 
(shRNA) constructs to attempt to significantly reduce IR translation. Four IR knock-
down constructs were used. Results show that cells transfected with an insKD construct 
exhibit slower proliferation rates than cell controls. The transfected cells also exhibited 
different proliferation morphologies. This research project was designed to bring insight 
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into the broader issue of possible strategies to combat cognitive decline in T2DM 
patients.  
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Introduction 
I. Background 
 Diabetes mellitus is a chronic disease that afflicts 29.1 million people in the 
United States and 347 million worldwide (American Diabetes Association 2014). It is 
caused by either a dysfunction of insulin secretion by pancreatic β cells or defects of 
the body’s ability to respond to insulin. Complications and co-morbid conditions 
include hypo/hyperglycemia, hypertension, diabetic retinopathy, stroke, kidney 
failure, myocardial ischemia, and lower limb amputations (American Diabetes 
Association 2014). The three main types of diabetes are diabetes mellitus type 1 (also 
known as juvenile diabetes or T1DM), diabetes mellitus type 2 (also known as adult-
onset diabetes or T2DM), and gestational diabetes. 
 T1DM is a result of the autoimmune destruction of β cells in the pancreas. β 
cells are essential for the production of insulin. Absence of these cells will lead to the 
body’s inability to produce insulin. As a result, since insulin is necessary for normal 
regulation of glucose transport into the cell, the body is defective in transporting 
glucose into insulin-dependent cells and thereby lowering the blood glucose level. 
Risk factors include viral exposure that may trigger the destruction of islet cells in the 
pancreas. 
In contrast, lifestyle, epigenetic, and genetic factors are the major predisposing 
elements to the onset of T2DM. T2DM accounts for approximately 90% of diabetes 
mellitus cases worldwide. T2DM patients may initially develop insulin resistance, an 
inability of the insulin receptors or their downstream signaling molecules to respond to 
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extracellular insulin, followed by the inability of β cells in the pancreas to produce and 
secrete sufficient insulin. Cells that are usually the most sensitive to insulin (adipose, 
liver, and skeletal muscle cells) may exhibit compromised metabolism as a result 
(Kahn et al. 2006). The most direct effect of insulin insensitivity is hyperglycemia, an 
increase in blood glucose levels. The insulin signaling pathway is impaired, which 
may result in physical complications that include peripheral neuropathy. Diabetic 
neuropathy (DN) presents with chronic pain and peripheral insensitivity; it is a major 
factor leading to lower limb amputations for T2DM patients (Dellon 2004). Current 
studies are also examining the possibility that T2DM may negatively affect central 
nervous system function, including cognition. 
 With 347 million afflicted worldwide, the disease is considered pandemic. 
Although our understanding of the disease has progressed tremendously since its first 
characterization by ancient civilizations, there is still a great need for further research. 
Research needs to elucidate more of the pathways involved with the disease. In 
particular, as diabetes is associated with increased risk of cognitive impairment 
(Espeland et al. 2013), there is a need to expand our knowledge of the role that insulin 
signaling impairment may have on neurodegeneration. This research project addresses 
a particular aspect of this field; our hypothesis is that neuronal death is increased due 
to dysfunction of the insulin signaling pathway. 
II. Insulin and its receptors 
 Insulin is a peptide hormone that is produced by pancreatic β cells. The 
primary function of insulin is to regulate metabolism by promoting glucose uptake 
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into the cell; as part of this insulin promotes the insertion of glucose transporters such 
as GLUT4 into the cell membrane. This lowers blood glucose concentration and 
promotes the conversion of glucose to glycogen for storage. Insulin also plays a role in 
lipolysis, cell growth, gluconeogenesis, and fatty acid and protein synthesis. Unlike 
steroid hormones, peptide hormones cannot diffuse through the cell membrane. In 
order for the hormone to induce signal transduction, it will either bind to an insulin 
receptor (IR) with high affinity or to an insulin-like growth factor-1 receptor (IGF-1R) 
with lower affinity. Both IR and IGF-1R are transmembrane receptors (Berg et al. 
2007). 
 The insulin receptor is encoded by the INSR gene; alternative splicing gives 
two protein isoforms: IR-A and IR-B. Posttranslational proteolytic cleavage of the 
insulin receptor results in an α and a β subunit. The complete insulin receptor consists 
of a dimer of two identical units; each unit of the dimer contains two subunits, α and β 
(Belfiore et al. 2009). The two subunits are linked by a disulfide bond. The α subunit 
is located in the extracellular region whereas the β subunit lies primarily embedded in 
the plasma membrane and inside the cell. The two α subunits bind together to form a 
dimeric unit binding site in the presence of insulin molecules. The β subunit has a 
receptor tyrosine kinase (RTK) domain that is able to catalyze the transfer of a 
phosphate from adenosine triphosphate (ATP) to the hydroxyl group of tyrosine. The 
insulin receptor is in its inactive form when the domain is not phosphorylated. When 
the two α subunits bind to insulin, the two protein kinase domains inside the cell come 
together. This allows for the activation loop of one β subunit to fit in the active site of 
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the other β subunit. In this position, the kinase domains will catalyze phosphorylation 
of the tyrosine residues in the activation loops using ATP, resulting in a conformation 
change and thus activating the insulin receptor (Berg et al. 2007). 
Once activated, the insulin receptor will initiate a cascade of downstream 
activity. The phosphorylated sites of the β subunit act as docking sites for substrates 
such as insulin-receptor substrate (IRS). The adaptor IRS protein contains four 
sequences that are preferred targets for the RTK domain; the phosphorylated insulin 
receptor is responsible for phosphorylating the tyrosine residues of IRS (Berg et al. 
2007).  Phosphorylated IRS will then engage in multiple downstream signaling 
pathways. The two primary ones are the phosphoinositide-3 kinase (PI3K)/Akt and the 
Ras/ mitogen-activated protein kinase (MAPK) pathways. The primary function of the 
PI3K/Akt pathway is to regulate enzyme activity. This pathway begins when PI3K 
converts PIP2 into PIP3. Once PIP3 is made, PIP3-dependent protein kinase becomes 
activated and subsequently activates Akt via phosphorylation. Once Akt is 
phosphorylated, it will phosphorylate and regulate downstream target proteins, mostly 
those involved in glucose metabolism. One major change is the movement of glucose 
transporters such as GLUT4 to the cell surface (Berg et al. 2007). The downstream 
actions of the Ras/MAPK pathway are primarily on transcription (i.e. gene expression) 
and cell proliferation. Ras is a monomeric GTPase that is regulated by guanine 
nucleotide-exchange factors (GEFs) and GTPase-activating proteins (GAPs). GEFs act 
by exchanging GTP and removing the GDP in Ras; GAPs stimulate hydrolysis of 
GTP, which inactivates Ras (figure 1). 
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 Ras is activated through the sequential activation of IR, IRS and Src homology 
2 domain containing protein (Shc). IRS acts as a docking site for Shc to bind and 
recruit Sos, a GEF, which promotes the activation of Ras. Activated Ras activates 
MAPK via a phosphorylation cascade involving Mek. Once MAPK is activated, it will 
phosphorylate other kinases as well as enter the nucleus to phosphorylate transcription 
factors to initiate gene expression (figure 2).  
 
 
 
 
Figure 2. A summary of 
the downstream actions 
of insulin binding to 
either IR or IGF-1R: 
When a ligand binds to IR, 
a downstream signaling 
cascade follows. The PI3K/ 
Akt pathway leads to 
stimulation of intermediary 
metabolism including 
glycogen synthesis from 
glucose. The Ras/MAPK 
pathway signals for cell 
growth and differentiation. 
(Eslam et al. 2011).  
α subunit 
β subunit 
Figure 1. GTPase in/activation through 
GEFs and GAPs.  
(Leonardy et al. 2010) 
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IGF-1 receptors are similar in structure and function to insulin receptors. Both 
have RTK domains and share common downstream pathways. Insulin is able to bind 
to both insulin receptors and IGF-1 receptors (to a lesser extent); IGF-1 has a higher 
binding affinity for IGF-1R than IR. It should be noted that IGF-1 receptors are more 
directly linked to mitogenic effects whereas insulin receptors are linked to both 
metabolic and mitogenic effects (Sciacca et al. 2012). 
 
III. Diabetes and the Nervous System 
 i) Peripheral Nervous System (PNS) 
 There has been increased interest in studying the cognitive ramifications of 
diabetes, particularly T2DM. Diabetic neuropathy occurs as a result of damaged 
nerves in the peripheral nervous system (PNS). The onset of diabetic neuropathy is 
thought to be caused by altered insulin signaling in neurons. A recent publication by 
Grote et al. (2013a) examined insulin signaling in non-diabetic mice administered 
varying doses of insulin. The study analyzed the phosphorylation of downstream 
proteins (Akt, GSK3β, mTor, ERK) in tissues that included the dorsal root ganglion 
(DRG), sciatic nerve (SN), liver, spinal cord, adipose, and muscle. Their primary 
objective was to determine whether the PNS is insulin responsive. The researchers 
also compared insulin signaling in the PNS with other peripheral tissues where insulin 
signaling is better understood (i.e. liver, adipose and muscle tissues). They found the 
SN had an increased response to insulin compared to the DRG. The downstream 
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signaling effects of insulin were reduced in both SN and DRG compared to non-
nervous tissues.  
 In a separate experiment, Grote et al. (2013b) investigated the presence of 
insulin resistance in the peripheral nervous system in ob/ob mice. ob/ob mutant mice 
have a mutation on the obese (ob) gene. This type of mouse is an obesity model since 
they eat excessively; they also have a high likelihood of developing T2DM. As 
described earlier, insulin resistance is a commonly observed symptom in T2DM 
patients. What remains unclear is whether the nervous system is altered in these 
patients. For their study, Grote et al. analyzed insulin receptor expression as well as 
the phosphorylation of kinases involved in the downstream signaling pathway in the 
DRG and the SN of the PNS. They found in vivo insulin resistance in the PNS and a 
blunted insulin response in ob/ob mice. Insulin receptor levels were significantly 
decreased in the DRG, and Akt phosphorylation was also significantly reduced in both 
the DRG and sciatic nerve (Grote et al. 2013b). Further studies are needed to elucidate 
the role of insulin signaling in the PNS.  
 ii) Central Nervous System (CNS) 
 Multiple studies have found that T2DM is linked to Mild Cognitive 
Impairment (MCI). Diabetes also increases the risk and rate of cognitive decline and 
dementia in older adults (Williamson et al. 2012). Because dysregulation of glucose 
metabolism and insulin homeostasis are common features of T2DM, insulin resistance 
in the CNS is a possible explanation for cognitive impairment.  
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 Both hypoglycemia and hyperglycemia have been implicated as causes of 
cognitive dysfunction. The pathophysiology of how hypoglycemia may impair 
memory over time is not well understood.  Kodl and Seaquist (2008) reviewed the 
literature on cognitive dysfunction in diabetes mellitus. They found that T2DM has 
been associated with decreases in several cognitive functions, including psychomotor 
speed, frontal lobe function, verbal memory, processing speed, complex motor 
functioning, working memory, verbal fluency, attention, and immediate and delayed 
recall. Despite these observed correlations, the degree of impact these cognitive 
deficits have on patients’ daily lives is difficult to quantify. For example, it is observed 
that T2DM patients are twice as likely to have depression, but this might be attributed 
to the negative effects of the lack of daily activities. The authors also observe that 
T2DM patients have an increased incidence of developing Alzheimer’s disease and 
vascular dementia (Kodl and Seaquist 2008). 
 Some studies on the presence of insulin in the brain suggest that insulin is 
produced locally in the CNS (Williamson et al. 2012). However, this remains a 
controversial topic. The current consensus is that insulin reaches the CNS via the 
blood-brain barrier through specific transporters (which have not been identified). In 
T2DM patients, hyperinsulinemia in peripheral tissues is commonly seen in the earlier 
stages; later, the increase in insulin is also found in the CNS. The increase in insulin 
levels has been shown to sensitize neurons to toxins and stress-induced factors 
(Williamson et al. 2012).  
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 In further support the idea that T2DM may lead to altered functions in the 
CNS, it has been well established that insulin receptors are present in multiple areas of 
the brain. There are quantitative differences in IR expression throughout the CNS; for 
example, IRs are highly concentrated in areas such as the olfactory bulb, pyriform 
cortex, amygdala, hippocampus, hypothalamus and various regions of the cerebral 
cortex (Marks et al. 1990). All of these areas play important roles in cognition. In 
addition, training mice through the Morris water maze leads to increased IR 
expression in the dentate gyrus, a region of the brain associated with neurogenesis and 
memory (Williamson et al. 2012). Clinical studies found that cognitive deficits in 
T2DM patients tend to be associated with hippocampus-related tasks. Surprisingly, 
neuron specific insulin receptor knock-out mice do not exhibit cognitive deficits. 
However, they do become hyperphagic and develop mild insulin resistance. This 
implies that IRs in the CNS contribute to maintaining homeostasis in the body 
(Williamson et al. 2012).  
 The mechanisms by which insulin regulates blood glucose levels in the CNS 
are still being elucidated. Glucose metabolism is the primary source of energy for 
neurons; glucose is transported into the cell via GLUT4 and other transporters. Insulin 
signaling normally increases movement of GLUT4 from intracellular endosomes to 
the cell membrane. When the uptake of glucose is reduced in T2DM, the supply of 
glucose in the neurons is diminished. Thus insulin may act as a regulator of neuronal 
metabolism in the CNS. In the case of insulin resistance, several studies have noted 
that vasoconstriction increased in the brain (El Khoury et al. 2014). This is predicted 
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to worsen the symptoms associated with T2DM, as impairment in blood supply 
delivery will decrease the amount of insulin delivered to the brain. In addition it will 
cause a decrease supply of nutrients and oxygen and impede the disposal of wastes 
and harmful metabolites. 
 Apart from acting as regulators for metabolism, studies suggest that insulin and 
its receptors are concentrated at neural synapses. This notion is particularly relevant 
for Alzheimer’s disease (AD). The brains of patients with AD exhibit two very well-
characterized phenotypes: amyloid plaques (or a soluble form as amyloid-beta 
oligomers) and neurofibrillary tangles made of tau proteins. T2DM patients have an 
increased risk of developing Alzheimer’s disease (AD) compared to their non-diabetic 
counterparts (Zhao et al. 2008). Other studies have found that major impairments in 
insulin and IGF-1 gene expression and signaling occur in the brains of AD patients (Li 
and Holscher 2007). This impairment could be due to the presence of soluble small 
protein (Aβ) oligomers (ADDLs), which have been found near synapses. For example 
Zhao et al. (2008) found that ADDLs were co-localized with a majority of insulin 
receptors in rats. Furthermore, they found that the presence of ADDLs caused a 
reduction of phosphorylation of IR, thus reducing its downstream activity. Other 
studies also suggest altered insulin signaling promotes the formation of neurofibrillary 
tangles through tau protein hyperphosphorylation (Lesort and Johnson 2000). Tau is a 
microtubule-associated protein that stabilizes the axon’s microtubules. When tau is 
phosphorylated, it decreases microtubule stability. When tau is hyperphosphorylated, 
18 
 
it may lead to aggregation of tau proteins and a prolonged period of destabilization of 
microtubules.  
 
IV. Porf-2 and Apoptosis 
 Cells can die due to injury or due to regulated developmental and functional 
processes. Cells that die due to injury will swell and burst, releasing factors that can 
trigger an inflammatory response and damage surrounding cells. This sequence of 
events is known as cell necrosis or passive cell death.  Three common types of 
regulated of Programmed Cell Death (PCD) are Type 1 (apoptosis), Type 2 
(autophagic) and Type 3B (cytoplasmic). PCD is defined as the “spatially and 
temporally reproducible and species-specific loss of large numbers of individual cells 
both during development and, in many tissues and organs, throughout life.” (Squire 
2013). The term ‘apoptosis’ is derived from a Greek word that means ‘falling away 
from’; it is characterized by shrinkage of cell size and condensation of nuclear 
chromatin. The cell membrane and organelles initially remain intact. Eventually, as 
the cell is fragmented, the cellular components will break apart and separate into 
smaller vesicles; the vesicles’ membranes will display phosphatidylserine and other 
phagocytic stimulating molecules. Phosphatidylserine is usually found on the cytosolic 
side of the cell membrane, but enzymes known as flippases transfer the 
phosphatidylserine to the exoplasmic side. Phosphatidylserine acts as a signaling 
molecule for macrophages to engulf the cell. Unlike necrosis, PCD is a carefully 
regulated process. Many proteins and their respective regulators act together to ensure 
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that the death of an individual cell will not interfere with the survival of the others 
surrounding cells (Squire 2013).  
There are two pathways for apoptosis: the intrinsic and extrinsic pathways. 
Much of our knowledge of the mechanism for apoptosis is derived from studies 
conducted on C. elegans. Because apoptosis is a tightly regulated process, many of the 
genes involved with the process are conserved across species. Important proteins 
Figure 3. 
Intrinsic/extrinsic 
apoptosis pathway: 
The intrinsic pathway is 
stimulated by factors 
inside the cell such as 
DNA damage or ER 
stress; the extrinsic 
pathway is a result of 
external ligands binding 
to specific cell-surface 
pro-apoptotic receptors. 
It is important to note 
that Bcl-2 and Bax/Bak 
may associate with the 
outer membrane of the 
mitochondria, which is 
not illustrated here 
(Degterev and Yuan 
2003). 
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include the B-cell lymphoma protein-2 family (BCL2) which is divided into three 
subclasses: anti-apoptotic (e.g. Bcl-2), pro-apoptotic (e.g. Bax, Bak, Bid), and BH3-
only (e.g. Bid, Bim, Noxa, PUMA) (Degterev and Yuan 2008). Bcl-2 proteins are 
present in the outer mitochondrial membrane; their roles include preventing pro-
apoptotic proteins, mainly Bax and Bak, from damaging the mitochondria.  
The intrinsic pathway is stimulated by factors within the cells such as DNA 
damage or extreme cell stress. These stimuli activate BH3-only proteins to reverse the 
effect of anti-apoptotic proteins such as Bcl-2 and induce Bax/Bak activation. Bax is a 
protein that is usually located in the cytosol. However, when activated, it can be 
translocated to the outer membrane where Bak resides (Degterev and Yuan 2008). 
Once the two proteins (Bax/Bak) begin to interact, it is hypothesized that they will 
form an oligomeric channel that will damage the mitochondria (figure 3). Cytochrome 
c, an electron transporter, is associated with the inner membrane of the mitochondria. 
It functions by transporting electrons between Coenzyme Q-cytochrome c reductase 
(complex III) and cytochrome c oxidase (complex IV) of the electron transport chain.  
When the mitochondrion becomes damaged by the pro-apoptotic factors Bax/Bak, 
cytochrome c is released into the cytosol. Cytochrome c will then bind to apoptotic 
protease-activating factor-1 (APAF-1) proteins, which promote the formation of a 
heptameric complex known as the apoptosome (figure 3). The apoptosome is 
composed of APAF-1 and procaspase-9 units. Caspases are a group of cysteine 
proteases that are present in the cell as zymogens (inactive proteins). They become 
activated when cleaved at specific sites on the protein. As its name suggests, APAF-1 
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helps activate procaspase-9 by transforming the zymogen to an active protease through 
a conformational change of the apoptosome. When caspase-9, known as the ‘initiator 
caspase’, is activated, it will act by cleaving other ‘executioner’ caspases (mainly 
caspases 3, 6, and 7). The executioner caspases will act downstream to induce 
apoptosis. For example, caspase 3 is essential for DNA fragmentation and chromatin 
condensation (Porter and Jänicke 1999). 
The extrinsic apoptotic pathway is initiated by pro-apoptotic and pro-
inflammatory cytokines such tumor-necrosis factor-α (TNFα). These factors bind to 
receptors on the plasma membrane known as death receptors. This binding will induce 
the formation of a complex known as the death-induced signaling complex (DISCs), 
which will activate an initiator caspase, procaspase 8, by cleavage. Caspase 8 can 
cleave and activate downstream caspases or may cleave a BH3-only pro-apoptotic 
protein Bid that will further signal mitochondrial damage (Degterev and Yuan 2008). 
The onset of apoptosis and other forms of PCD are tightly regulated. p53 is a 
tumor-suppressor protein that acts upstream of p21. TP53 (tumor protein 53) is the 
gene which encodes p53; the protein has transcriptional activation, DNA binding, and 
oligomerization domains (Macleod et al. 1995). When a cell receives genotoxic or 
non-genotoxic stress signals such as upstream apoptotic signals, p53 is stabilized by 
phosphorylation; once stabilized, it will act to increase transcription of p21 (Gartel and 
Tyner 2002).  
Cyclin-dependent kinases (CDKs) are enzymes involved in cell-cycle 
regulation. When forming a complex with cyclins, CDKs may be activated and 
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contribute to cell-cycle progression (Gartel and Tyner 2002). In order to regulate cell 
progression, proteins known as cyclin-dependent kinase inhibitors (CDKIs) may be 
expressed. CDK inhibitor-1 (p21) is a CDKI that inhibits cyclin bound-CDK1, -
CDK2, and –CDK4/6 by binding to the complex; a conserved region at the N-terminus 
of p21 is believed to be necessary for inhibiting cell cycle progression. p21 
downregulates cell proliferation (Xiong et al. 1993).  Paradoxically, p21 has varied 
effects on apoptosis: it may prevent apoptosis, or promote apoptosis through either a 
p53-dependent and/or independent pathway.  
Preoptic regulatory factor 2 (Porf-2) is a protein that was discovered in the 
preoptic area of the hypothalamus (Nowak et al. 1999). Porf-2 expression is present in 
other tissues including the cerebral cortex, the anterior pituitary, cerebellum, testes, 
kidneys, liver, skin, and other peripheral tissues. The porf-2 gene is present in a wide 
array of animals which include the rat, mouse, chicken, pig, sheep, cow, zebrafish, and 
human (Hayat 2014). Expression of Porf-2 varies with both age and sex (Nowak 
2003). Porf-2 contains a RhoGAP domain, which is an inactivator of RhoGTPases. 
Abnormal RhoGAPs are linked to neurodevelopmental disorders such as X-linked 
mental retardation and to neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS) (Etienne-
Manneville 2002). RhoGTPases (one of five major types of small G-protein GTPases: 
Rho, Ras, Rab, Arf, and Ran) have functions including regulating cell polarity, gene 
transcription, G1 cell cycle progression, cytoskeleton structure maintenance, dendritic 
spine formation and excitatory synapses, among others (Linseman and Loucks 2008).  
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Previous studies have indicated that Porf-2 may regulate growth in the 
developing central nervous system (CNS). Porf-2 knockdown neural stem cells were 
shown to have a higher percentage of cells in the S phase than in the G1 phase when 
compared to control cells (Ma and Nowak 2011). The knockdown cells underwent 
significantly less apoptosis when they were exposed to proapoptotic factors such as 
bleomycin and staurosporine (STS). STS is derived from the bacterium Streptomyces 
staurosporeus; it is a protein kinase inhibitor. It acts by preventing ATP from binding 
to the kinase catalytic domain. The exact mechanisms by which it induces apoptosis is 
not well understood, but it is suggested that it acts through caspase-3 activation. 
Bleomycin, produced by Streptomyces verticillus, is a genotoxin, which initiates 
apoptosis by damaging the DNA in cells (Ma and Nowak 2011).  
The results of these studies indicate that Porf-2 exhibits pro-apoptotic and anti-
proliferative properties. It decreases cell metabolism and increases cell apoptosis 
through p53-dependent and –independent pathways in neural stem cells (figure 4). 
Increased rates of apoptosis, when not offset by cellular proliferation, may lead to 
degenerative diseases in the nervous system.  
24 
 
 
 
V. Insulin and Porf-2 Pathways 
 Insulin may induce cell proliferation and stimulate metabolism when bound to 
either an insulin or IGF-1 receptor. By activating the PI3K/Akt and/or the Ras/MAPK 
pathway, the binding of insulin leads to transcription initiation, beginning the process 
of cellular proliferation. In contrast, studies on Porf-2 show its anti-proliferative 
properties, most likely through cycle arrest. As shown in figure 4, Porf-2 may act via a 
p53-dependent and/or –independent pathway. It is apparent that the insulin and Porf-2 
effects are opposing. Because of this, it is of interest to us to further understand the 
interaction between insulin and Porf-2 and its possible role in T2DM. A common 
characteristic associated with T2DM is that insulin receptors become insensitive. This 
will lead to reduced downstream insulin/IGF-1 signaling. As described below, 
Figure 4. Porf-2 
signaling 
cascade. The 
downstream 
effects are 
decreased 
proliferation and 
increased 
apoptosis (Ma and 
Nowak 2011). 
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preliminary results indicate that insulin represses expression of Porf-2, which would 
‘protect’ the pro-metabolic role of insulin. As a result, Porf-2 may play a role in 
promoting signaling for a reduction in cell proliferation as well as an increase in 
apoptosis when insulin signaling is altered. The link for these two pathway remains to 
be elucidated.  
 
VI. Fischer’s Rat Thyroid Cell Line-5 (FRTL-5) 
Fishcer’s Rat Thyroid Cell Line (FRTL-5) cells are derived from cloned 
normal Fischer rat thyroid cells. When cultured in vitro, the cells express many 
thyroid-differentiated markers such as those for epithelial morphology, cytoskeleton 
organization, and iodine uptake. The cell morphology is polygonal and the cells grow 
as a monolayer. Thyroid cell function is regulated by thyroid stimulating hormone 
(TSH), which has a trophic effect on the cells. TSH is needed for FRTL-5 cell growth 
and differentiation. In the absence of TSH, they will become non-proliferative 
(Mulcahy et al. 1985).  
IR and IGF-1R are both tyrosine kinases composed of two alpha and two beta 
subunits. Both receptors are homologous and are monomers when inactive; the 
receptors become functional and signal transduction will occur when the monomers 
dimerize after binding of insulin or IGF-1. Due to the homology of IR and IGF-1R, 
one monomer of each can combine and produce a hybrid IR/IGF-1R. As discussed 
earlier, insulin ligand binds to IR and induces signal transduction; insulin binds with 
lower affinity to the hybrid IR/IGF-1R, which can also induce a downstream signal. 
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IGF-1 can also bind to the hybrid receptor with greater affinity than insulin, as well as 
to its own receptor. FRTL-5 cells were used in this research project because of the 
presence of both IR and IGF-1R on the cell membrane. This allows for potential 
hybridization of the two receptors.  
 
VII. Previous Research 
Previous research conducted by F. Nowak and Z. Wang investigated the effects 
of the insulin and IGF-1 signaling pathways on Porf-2 expression in FRTL-5 cells. 
When FRTL-5 cells are treated with 0-100 ng/mL IGF-1, Porf-2 mRNA expression 
levels decrease in a dose-dependent manner. Similarly, cells incubated in medium 
containing insulin have decreased Porf-2 mRNA expression levels with 100ng/mL and 
1000ng/mL of insulin present. Maximal Porf-2 expression level suppression was 50% 
with insulin whereas for IGF-1, it was 60% (Wang 2011).  
When FRTL-5 cells were exposed to specific protein inhibitors of the insulin 
and IGF-1 pathway, the IGF-1 effect on Porf-2 mRNA expression levels was blocked. 
LY294002 and wortmannin, Akt Inhibitor IV, Raf kinase Inhibitor IV, and PD98095 
were used to inhibit PI3K, Akt, Raf kinase, and MAPKK respectively. IGF-1 was used 
as the ligand to bind to IGF-1Rs and IRs and subsequently activate the downstream 
signaling. When cells were exposed to Akt inhibitor IV, LY294002 or Raf-kinase 
inhibitor PD 98095, the effects of IGF-1 on Porf-2 were partially blocked (figures 5 
and 6). Wortmannin, which inhibits both PI3-K and MAPKK, blocked the effect of 
IGF-1 on Porf-2.  
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Z. Wang also conducted IGF-1 receptor knock-down experiments through the 
use of small-hairpin RNA (shRNA). shRNA is a gene silencing technique that uses 
artificially designed RNA sequences to repress the expression of a target mRNA. As 
predicted, knockdown of the IGF-1R partially suppressed the effects of IGF-1 on 
expression of Porf-2. Overall, the research indicates that insulin and IGF-1 signaling 
pathways influence Porf-2 expression levels, thus creating a link between IGF-1 and 
Porf-2 (Wang 2011).  
Figure 5: Porf-2 expression levels are inhibited by IGF-1. This inhibition is blocked in a 
dose-dependent manner when PI-3K (Wormannin and LY294002) inhibitors are added 
(Wang 2011).    
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Figure 6: Porf-2 expression levels are decreased after IGF-1 application and increased 
when various downstream IGF-1 signaling proteins inhibitors are added: (A) Akt 
inhibitor, (B) Raf kinase inhibitor and (C) MAPKK inhibitor (PD98095) (Wang 2011).   
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Hypotheses and Significance 
I. Hypotheses 
The aim of this project is to further characterize signaling pathways that 
mediates effects of IGF-1 and insulin on Porf-2 expression. We hypothesize that when 
insulin and IGF-1 receptor functions are significantly decreased, that Porf-2 
expression will increase. Furthermore, we hypothesize that the downstream signaling 
proteins will show altered protein activity levels; this includes a decrease in 
phosphorylation of essential downstream kinases as compared to controlled cells.  
As discussed above, insulin and IGF-1 share signaling pathways. However, 
there are important distinctions between the two. First, insulin and IGF-1 have 
different binding affinities for their respective receptors. Insulin has a higher binding 
affinity for insulin receptor than IGF-1R. Conversely, IGF-1 has higher binding 
affinity for IGF-1R than insulin receptors. My specific hypothesis is that knocking 
down the insulin receptor will partially block the effects of insulin and IGF-1 on Porf-
2. My specific aim is to knock-down the IR in FRTL-5 cells and measure the effect on 
Porf-2 mRNA.  
 
II. Significance 
 Previous studies have demonstrated links between insulin and IGF-1 resistance 
and cognitive impairment. It is also known that patients with T2DM are more likely to 
develop neurodegenerative diseases, in particular Alzheimer’s disease. It is important 
to note that many neurodegenerative diseases are associated with decreases in brain 
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volume, most likely through increased apoptosis. There are proposed pathways by 
which insulin insensitivity may exacerbate neuronal dysfunction and cognitive 
impairment. As described above, insulin receptors present at neural synapses co-
localize with amyloid beta derived diffusible ligands in Alzheimer’s disease patients. 
Previous research has shown that Porf-2 has anti-proliferative and pro-apoptotic 
properties. Thus, there may be a link between insulin/IGF-1 deficiency or resistance 
and neurodegeneration and Porf-2 expression.  
 By studying FRTL-5 cells, we hope to provide an in vitro model to study 
whether insulin/IGF-1 insensitivity results in an increase of Porf-2 expression. We 
plan to explore the downstream signaling pathways of insulin/IGF-1 and Porf-2. The 
ultimate goal of this research project is to establish a deeper mechanistic 
understanding of how Porf-2 may be involved in the cognitive impairment and 
possibly other complications seen in T2DM patients.   
 
 
Experimental Designs and Methods 
 
 
I. FRTL-5 cells and Cell Culture 
The Fischer rat thyroid cell line (FRTL-5) was used for this study. Cells were 
cultured in cell culture dishes with media composed of 5% heat-inactivated bovine 
serum, nonessential amino acids, Coon’s modified Ham’s F-12 (Sigma-Aldrich, St. 
Louis, MO), and six hormones (TSH, insulin, somatostatin, hydrocortisone, 
transferrin, and glycyl-histidyl-lysine). Cells were incubated in a Heracell™ CO2 
incubator at 37˚C and 5% CO2. After reaching 70-80% confluence, the cells were split 
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into multiwell plates for further growth. Media was changed after 3-4 days by 
aspiration (Kohn and Valente 1989). 
 
II. Optimum Blasticidin Concentration 
Prior to transfection, the optimal blasticidin concentration needed to be 
determined. Blasticidin is an antibiotic that acts on both prokaryotes and eukaryotes. 
We used it as a selection agent for transfected cells. Although blasticidin is needed to 
control for the presence of the vector in transfected cell cultures, a high concentration 
of the selective agent can impede cellular proliferation and the transfection efficiency. 
Also, a low concentration of blasticidin will not successfully select against non-
transfected cells. Therefore, an optimal blasticidin concentration is needed 21 hr after 
transfection to select for successfully transfected cells. Previous tests by Z. Wang 
showed that the ideal length of time for selective killing of FRLT-5 cells in blasticidin 
Figure 7. Schematic for determining optimum blasticidin concentration.   
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was around 2-3 weeks (Wang 2011). To determine the optimal selective concentration, 
various concentrations of blasticidin were tested on non-transfected FRTL-5 cells. 
Once the FRTL-5 cells reached 70-80% confluence, the cells were split into two 6-
well culture plates with a growth area of 9.5cm2 for continued proliferation. After the 
cells reached ~30% confluence, selected wells were given a set concentration of 
blasticidin. The concentrations of blasticidin that were tested were: 0, 4, 5, 6, 8, and 10 
μg/mL. Duplicates of each concentration were performed to establish the optimum 
blasticidin concentration to use for selection after transfection.  
The optimal concentration was determined by measuring the number of days 
necessary to eliminate the entire population of non-resistant cells in each well while 
preserving as many resistant cells as possible. Previous testing also showed that 
blasticidin concentrations lower than 3µg/mL were not effective at killing all 
nonresistant cells within the selective time frame (data not shown). Therefore, 
blasticidin concentrations lower than 4ug/mL were not tested.   
 
III. Transfection  
After establishing the optimal blasticidin concentration, new FRTL-5 cells 
were cultured in culture dishes and split into individual plates once they reached 60-
70% confluence. Transfection began when the newly split cells reached 60-70% 
confluence. Insulin receptors were targeted for knocked-down via transfecting the 
cells with plasmid sequences that contain short hairpin RNA (shRNA). These RNAs 
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were designed to bind to the transcribed mRNA coding for the insulin receptor and 
decrease its protein expression.   
Decreasing insulin receptor expression by using shRNA transfection was 
preferred over other RNA interference (RNAi) approaches. shRNA uses DNA 
plasmids as vectors that allows for stable incorporation and selection of cell lines that 
have reduced expression of a specific gene. Once shRNA plasmids are introduced into 
the cell, they generally accumulate in the nucleus. In the nucleus, the shRNA are 
synthesized by either RNA polymerase II or III and form a hairpin structure that 
consist of a paired stem region and unpaired sense strands (figure 8).  The shRNA is 
then exported out of the nucleus. Dicer protein is an enzyme that is part of the RNase 
III family that cleaves double stranded RNA (dsRNA) into short, dsRNA fragments. 
In the cytosol, the shRNA RNA will form a complex with Dicer and will be processed 
Figure 8. The shRNA plasmid is transcribed from DNA into shRNA; shRNA 
consists of sense and anti-sense sequences (O’Keefe 2013).  
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and cleaved into a small interfering RNA (siRNA). The double stranded siRNA will 
then bind to the RNA-induced silencing complex (RISC). RISC separates the dsRNA 
and removes one of the strands. When the single stranded siRNA that remains bound 
to the RISC binds to the mRNA of interest by complementary base pairing, then RISC 
cleaves the mRNA in a sequence-specific manner (figure 9) (Taxman et al. 2010). 
Figure 9. Schematic for shRNA delivery and function in the cell (SantaCruz 
Biotechnologies 2014) 
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shRNA should not exceed 30 base pairs (bp); this avoids the double-stranded 
(ds) RNA of FRTL-5 cells from triggering an antiviral response to the transfection 
(Origene Technologies 2015). We selected 4 different insulin knock-down (insKD) 
shRNAs designed by Origene Technologies (Rockville, MD); each insKD construct 
contains a 29 bp sequence stem designed to bind to a specific portion of the IR mRNA 
and a 7 bp loop to form the hairpin structure (figure 10). Empty vector (CO) and 
scrambled vector (CS) inserts were used as controls. The CO plasmid has a sequence 
that encodes for blasticidin resistance but does not contain a 29 bp construct sequence. 
The CS plasmid also contains a sequence that encodes for blasticidin resistance and 
includes a random 29 bp that is not complementary to the insulin receptor gene. CO 
plasmid was used to show that vector transfection has no effect of the cells, other than 
providing it with blasticidin resistance. CS plasmid was used to demonstrate that the 
binding of the insKD constructs was specific. Each plasmid vector also contains a U6 
promoter site for shRNA expression and a SV40 promoter site for blasticidin 
resistance expression.  
FuGene HD transfection reagent (Promega, Madison, WI) was used for 
transfection. Fugene HD is a non-liposomal transfection reagent; the non-liposomal 
lipids in FuGene HD form complexes with the plasmid vector in the form of micelles. 
OptiMEM (ThermoFischer Scientific, Grand Island, NY), a reduced serum media, was 
used during transfection; this media enables the formation of an amphiphilic 
compound with a micelle core containing the DNA. DNA is delivered into the cell by 
micelle fusion with the cell membrane.  
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 After newly split FRTL-5 cells reached 60-70% confluence, media was 
removed by aspiration and replaced with 1mL of OptiMEM in each 9cm2 plate. A 
small volume of OptiMEM and DNA (see Table 1) was incubated in a 250μL tube for 
5min before adding Fugene HD transfection reagent directly into the mixture. The 
mixture was then incubated at room temperature for 15 min before adding it into each 
individual plate. Cells from each plate were given a specific combination of reagent 
mixture for transfection (table 1). The cells were incubated for 24hr at 37 °C in the 
mixture. After 24hr, the OptiMEM mixture was removed by aspiration and replaced 
with regular cell media. Plates 3-9 were also given 4μg/mL of blasticidin. Cells were 
observed and photographed with a Nikon Eclipse TS100 inverted microscope. 
 
 
 
 
 
   
Reagent Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Plate 6 Plate 7 Plate 8 Plate 9 
OptiMEM 25 μl 22μl 22μl 15.5μl 15.5μl 15.5μl 15.5μl 15.5μl 15.5μl 
DNA - - - 7.5μl 
C0 
7.5μl 
CS 
7.5μl 
insKD-
A 
7.5μl 
insKD-
B 
7.5μl 
insKD-
C 
7.5μl 
insKD-
D 
Fugene HD no 2μl 2μl 2μl 2μl 2μl 2μl 2μl 2μl 
Blasticidin no no yes yes yes yes yes yes yes 
Table 1: Reagents used for transfection. CO=vector only, CS=scrambled insert.
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      1 cccacccaga gctgcgcgga gaggagaaac gggagacccg gccaggggac gcaccttggt 
61 gagctctgga ctctgcgatt gcggacacag gaccgggcct gggtgacccg gggttgtagt 
121 ctgcgggccg cgccacagtg ttgcttgcag ccgaggcctg tgtgctcttc ccaggactgt 
181 ccccagggcc ctctaggctg gagatctgcg gcccgtaagc caccggcgtg gaagagaagg 
241 acgtgcggcc cctagcgcct gcctctccag cgaccttctc gcggagtatg tccccagtgg 
301 gccggcgtgg cgtgctctga tcgccggggt cccagcgctc ctactgctat gggctccggg 
361 agaggatgtg agacgacggc ggtgccgttg ctgatggccg tggccgcgtt gctggtgggc 
421 acagccggcc acctgtaccc tggagaggtg tgcccgggaa tggacatccg gaacaacctg 
481 accaggttgc atgagctgga gaactgctcg gtcattgagg gccatctgca gatcctcttg 
541 atgttcaaga ccagacccga agatttccga gacctcagtt tccccaaact catcatgatc 
601 acagactacc tgcttctttt ccgtgtctat ggcctagaaa gtctaaaaga cctcttccca 
661 aacctcacag tcatccgagg ctcccgtctc ttcttcaact atgccctggt catcttcgag 
721 atggtccacc tgaaggagct gggtctttac aacctcatga acatcacccg gggctctgtc 
781 cgcatcgaga agaataatga actctgctac ctggccacta tcgactggtc ccgcatcctg 
841 gattccgtgg aggacaacta cattgtactg aacaaagatg acaatgagga atgtggggac 
901 gtctgtccag gcacagccaa gggcaagacc aactgccctg ccaccgtcat caatgggcag 
961 tttgtggaac ggtgctggac acacagtcat tgtcagaaag tttgcccaac catctgtaag 
1021 tcacatggct gcacagctga aggcctgtgc tgtcacaagg agtgcctggg caactgttca 
1081 gaacccgatg accctaccaa gtgtgtggcc tgtcgaaact tctacctgga tggtcagtgt 
1141 gtggagacct gcccaccacc ctactatcac ttccaggatt ggcgctgtgt aaacttcagc 
1201 ttctgccaag accttcacta caaatgcagg aactctcgga agcctggctg tcaccaatac 
1261 gtcattcaca acaacaagtg catccccgag tgcccgtctg gctataccat gaattccagc 
1321 aacttgatgt gcaccccgtg tctgggaccc tgtcctaagg tctgccaaat cctcgaaggc 
1381 gagaagacca ttgattccgt gacatctgcc caggagctcc gaggctgcac tgtgatcaat 
1441 ggcagcctga ttatcaacat ccgagggggc aacaacctgg cagctgaact agaggctaac 
1501 cttggcctca ttgaagaaat ctcagggttc ctaaagatcc gtcgctccta tgctctggtg 
1561 tcactttctt tcttcaggaa gctacatctg attcgaggag agaccttgga aattgggaac 
1621 tattctttct acgccttgga caaccagaac ctgaggcagc tgtgggactg gaacaagcac 
1681 aacctcacga tcactcaggg caagctcttc ttccactaca accccaaact ctgcctgtct 
1741 gagatccaca agatggagga agtgtccgga accaagggcc gccaggagag gaacgacatt 
1801 gccctgaaga ccaacgggga ccaggcatcc tgtgaaaatg aattacttaa attctctttc 
1861 atccggacgt cttttgacaa gatcttgctg aggtgggagc cctactggcc ccccgacttc 
1921 cgagatctcc tgggattcat gctgttctac aaagaggccc cttatcagaa cgtgacagag 
1981 tttgacgggc aggatgcgtg tggctccaac agctggactg tggtggatat tgacccgccc 
2041 cagaggtcca acgaccctaa gtctcagacc ccaagccacc ctgggtggct gatgcggggc 
2101 ctcaaaccct ggacccagta tgccatcttt gtcaagacct tggttacctt ctctgatgaa 
2161 cgccggacct atggagccaa aagtgatatc atctatgtgc aaacagatgc caccaatcct 
2221 tccgttcccc tggatcccat atcagtttcc aactcctcat ctcagattat cttaaagtgg 
2281 aagcccccct cggaccccaa tggcaacatc acacactacc tggtctactg ggagaggcag 
2341 gcggaggaca gcgagctgtt cgagttggat tattgtctca aagggctgaa gctcccctca 
2401 cgcacctggt ccccaccttt tgagtctgac gattctcaaa agcacaatca gagtgagtat 
2461 gacgactcgg ccagcgagtg ctgctcatgt cctaagactg actctcagat cctgaaggag 
2521 ctggaggagt cttcattcag gaagaccttc gaggattacc tgcacaacgt ggtttttgtt 
2581 cccagaaaaa cctcttcagg caatggtgct gaggacacta ggccatcccg aaagcgaaga 
2641 tcccttgaag aggtgggcaa tgtgacagcc actacaccca cacttccaga ttttcccaac 
2701 atctcctcca ccatcgcgcc cacaagccac gaagagcaca gaccatttga gaaagtagta 
2761 aacaaggagt cacttgtcat ctctggcctg agacacttca ctgggtaccg cattgagctg 
2821 caggcatgca atcaggactc cccagaagag aggtgcagcg tggctgccta cgtcagtgcc 
2881 cggaccatgc ctgaagctaa ggcagatgac atcgttggcc ctgtgaccca tgaaatcttt 
2941 gagaacaatg ttgtacactt aatgtggcaa gagccaaagg aacctaatgg tctgattgtg 
3001 ctatatgaag tgagctatcg gcgatatggt gatgaggagc tgcacctctg tgtctcccgg 
3061 aagcattttg ccctggagcg gggctgcagg cttcgagggc tctctccagg aaactacagt 
3121 gttcgagtcc gggctacctc tctggcagga aatggctcct ggacagaacc cacctatttt 
3181 tatgtgactg attatttaga tgtcccatca aatattgcca aaattatcat cgggcccctc 
3241 atcttcgtct tcctcttcag tgtcgtgatc ggaagtattt atctattctt gaggaagagg 
3301 cagccagatg ggccaatggg accactgtac gcttcttcaa acccagagta cctcagtgcc 
3361 agtgatgtct ttccatcttc cgtatacgtt ccggatgagt gggaggtacc tcgagagaag 
3421 atcaccctcc tccgagagct ggggcaggga tccttcggta tggtgtacga aggcaatgcc 
3481 aaggatatca tcaagggtga ggtagagacc cgtgttgcgg tgaagacggt caatgagtca 
3541 gccagtcttc gagaacggat cgagttcctc aatgaggcat cagtcatgaa gggcttcacc 
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3601 tgtcatcacg tggtccgcct tcttggggtg gtgtccaaag gccagcccac attggtagtg 
3661 atggaactga tggctcatgg agacctgaaa agtcacctcc gttctctgcg gcccgatgct 
3721 gagaacaacc caggccgtcc tccccctacc ttgcaagaaa tgattcagat gacagcagaa 
3781 attgccgatg gcatggcata cttgaacgcc aagaagtttg tgcaccggga cctggcagct 
3841 cggaactgca tggttgccca tgattttact gtcaaaatcg gagactttgg aatgacgaga 
3901 gacatctacg agacagatta ctatcggaaa gggggcaagg ggttgctgcc cgtgaggtgg 
3961 atgtcacccg agtccctgaa ggacggagtc ttcactgctt cttccgacat gtggtccttt 
4021 ggggtggtcc tttgggaaat caccagcctg gctgagcaac cttaccaagg cctgtctaat 
4081 gaacaggtgt tgaaatttgt catggatgga ggctatctgg atccccctga taactgtcca 
4141 gagagactca ctgacctgat gcgcatgtgc tggcagttca accccaagat gaggccgacc 
4201 ttcctggaaa tcgtcaacct gctcaaggac gacctccacc ccagctttcc ggaagtttcc 
4261 ttcttctaca gcgaggagaa caaggctccc gagagtgaag agctggagat ggagttcgag 
4321 gacatggaga atgtcccctt ggatcgttcc tctcactgtc agagagaaga ggctggatgc 
4381 cgggagggag ggtcctctct gagcatcaaa cggacctatg atgaacacat cccctacacc 
4441 cacatgaacg ggggcaagaa gaatgggcgg gtcctcaccc tgccgaggtc gaacccttcc 
4501 taacagcgcc tgctcgctcg gggaaggatt cttttctttt ctttctttct ttttaaaaac 
4561 tcttctgtag tttgactgcc tccaggaaac tcaggattat cgggactcta cccagatgtg 
4621 aaactgagct cacagatagt tcgtacacat ttctgtttgt ctttggacct gaaaacacac 
4681 aggtgtggtc gccaaccctg cgagcctgtg gagggctaac tgtgaaccta gaggggttgg 
4741 ggtttccata ctcccttccc tgcccccacg gtatcaaacc aagattttat tgttgttgct 
4801 ggtgttttcc tcatagattg gaaggatgaa cctgttttta cagttttttt tttctgctag 
4861 tgtctgagtt atagttagtt gtcaaagaca gactttattt atggagcaca agtcagaaag 
4921 caaagaagaa acagacagaa aaacaaaaca aaaaccaaac ctgacctaca gaacccagtt 
4981 ctggaattgc gtgctttcgc ggggttgggc tttgagaagg tttcattaat ctgagagaag 
5041 gagcttattt tattttagtt ttgttttgtt tttttcctca ttcacaaaat cagttcctca 
5101 aattgaccaa tagctgctgc tttcatattt tattattttg ggaaagggtg tgtactccta 
5161 agtgtgtgct catctgcaca cctgcgtgca tttgcgtgtg tgttgtgtcc aggttagaga 
5221 tcacagggtg gggtgggggc tgtgtgtatg ttacattttt ctctggactg atgcttggtg 
5281 acttggctca tgaagcaccc gctgcttgga gtgggtgacc tcatattgtc ctcttccttc 
5341 ttatgaaccg agagcttgtg ccctcgagag attctcctca gtcacgtcag aactcgctc 
// 
 
Figure 10. Nucleotide sequence of IR. insKD A (yellow) and insKD B (pink)  are 
complementary to regions of the alpha chain sequence; insKD C (green) is complementary to 
the crossing sequence between alpha and beta chains; insKD D (blue)  is complementary to 
the sequence that is located at the very end of the IR beta subunit. Insulin receptor subunits 
alpha and beta span from 427-2628 and 2641-4500 respectively (NCBI 2014). 
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IV. Future Experiments: Western Blotting 
 
Western Blot will be used once ~107 cells are obtained. Cells will be detached 
and lysed to extract the appropriate proteins. A 10% gel percentage will be used for 
polyacrylamide gel electrophoresis. Insulin Rβ	Antibody (C-19)	ሺSanta Cruz 
Biotechnology, Pasa Robles, CA) is a primary rabbit polyclonal antibody that can be 
used for detection of IR β subunit on mouse, rat, and human cells. Insulin Rβ	
Antibody will be used in parallel with positive and negative controls. The predicted 
size for insulin receptor subunit beta is around 95 kDa. For the positive controls, 
untransfected FRTL-5 cells will be used to compare IR expression levels with FRTL-5 
cells transfected with control or experimental constructs. In addition, NIH 3T3 (mouse 
embryonic fibroblast cell line) whole-cell lysates will be used as a positive control. As 
our negative control, peptide antagonists (Santa Cruz Biotechnology, Pasa Robles, 
CA) will be incubated with the insulin receptor before applying the primary antibody; 
this should block all antibody binding to IR. After incubating the membrane with a 
secondary antibody, enhanced chemiluminescence (Thermo Fischer Scientific, Grand 
Island, NY) will be used to visualize protein expression levels.  
In addition, Western blots will be run using cells from a previous project that 
have been transfected with shRNA that knocks-down the IGF-1 receptor. IGF-1Rβ 
Antibody (C-20) (Santa Cruz Biotechnology, Pasa Robles, CA) is a primary rabbit 
polyclonal antibody that is used for detection of IGF-1Rβ	subunit on mouse, rat, and 
human cells. Positive and negative controls will be used.  
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V. Future Experiments: qPCR   
 Once protein expression levels for each individual insKD construct have been 
established, knock-down cell lines will be used to measure Porf-2 and IR mRNA 
expression levels using real-time polymerase chain reaction (RT-PCR). This method 
of analysis allows us to measure the amount of mRNA present in cells by using 
reverse transcriptase to transcribe mRNA in the cell to cDNA. SYBR Green (Bio-Rad 
Laboratories Inc, Hercules, CA) will be used to quantify the cDNA in qPCR. The 
housekeeping genes beta-actin and histone H3 will be used as a loading control. 
 
Table 2. Primer sequences for qPCR. F- forward primer; R- reverse primer (Wang 
2011) 
  
IR F 5’-TCCTCAAGGAGCTGGAGGAGT-3’ 
 R 5’-GCTGCTGTCACATTCCCCA-3’ 
IGF-1R F 5’-GCCAGAACCCGAGAACCC-3’ 
 R 5’-ACACATTCCCGCTGATCCT-3’ 
Porf-2 F 5’-TTCCTCCAGGTGTTCGTC-3’ 
 R 5’-TGGTATCTAAATGCTGAATGAG-3’ 
β-actin F 5’-GGGAAATCGTGCGTGACATT-3’ 
 R 5’-GCGGCAGTGGCCATCTC-3’ 
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Results 
I. Optimum Blasticidin Concentration 
Blasticidin was the selective reagent used for selecting transfected cells. It is a 
nucleoside antibiotic isolated from Streptomyces griseochrmogenes. It acts to inhibit 
protein synthesis. Although transfected cells have a gene whose product provides 
blasticidin resistance, high concentrations of blasticidin will impede cell proliferation. 
At optimal blasticidin concentration, the reagent will select for successfully 
transfected cells while also ensuring that the reagent will not fully disrupt cell 
proliferation.  
To determine optimal blasticidin concentration, non-transfected FRTL-5 cells 
were cultured in 6-well plates; once all cells reached 30% confluence, varied 
concentrations of blasticidin were added to determine the optimal concentration to use 
for selecting transfected cells.  After two weeks, all normal cells given a blasticidin 
concentration of 8μg/mL or 10μg/mL died. After 13 days, all cells given a blasticidin 
concentration of 5μg/mL or 6μg/mL lost normal cell morphology and only 5-10% of 
cells remained attached to the well. It was therefore determined that a blasticidin 
concentration of 4μg/mL is optimal for selecting transfected cells, as all cells died 
within 17 days, which is within the recommended selection period (data not shown). 
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Table 3. Cell confluence was observed and estimated with a Nikon Eclipse 
TS100 inverted microscope. 
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II. Stable Transfected Cell Lines 
 
Based on preliminary results, cell culturing techniques were altered during 
transfection. After reaching 70-80% confluence, cells were originally split into two 
multi-well plates (9.5cm2 /well). However, due to problems with bacterial 
contamination, possibly as a result of long incubation times in connected wells, it was 
decided that FRTL-5 cells should be split into individual, 9cm2 plates and be replated 
and amplified in 55cm2 plates. 
 21 hr after transfection, cells were given 4μg/mL of blasticidin. Although the 
transfected cells in this study carried the blasticidin resistant gene (BSDr), the reagent 
still decreased cell proliferation. Non-transfected, FRTL-5 cells without blasticidin 
reached confluence in two weeks (figure 11). In contrast, none of the transfected cells 
reached confluence within two weeks in blasticidin (4μg/mL). FRTL-5 + Blasticidin 
cells were used as the negative control; all the cells died within 18 days when grown 
in parallel with transfected cells. To improve growth of transfected cells, the 
transfected plates were placed in a reduced concentration of blasticidin (2μg/mL) once 
all the cells from the FRTL-5 + blasticidin (4μg/mL) plate had all died (at day 18).  
Empty (CO) and scrambled (CS) insert vector controls had accelerated growth 
when blasticidin concentration was reduced to 2μg/mL 18 days after transfection 
(figures 12 and 13). Cells from both CO and CS vector insert plates reached 
confluence within two and three weeks after reducing blasticidin concentration, 
respectively. Transfected cells with insKD constructs had much slower growth rates 
(figures 12 and 13). insKD C and D cells reached confluence after four weeks of 
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growth in 2μg/mL of blasticidin. insKD B cells reached confluence after nine weeks 
of growth, and insKD A cells have not yet reached confluence at the conclusion of the 
research (twelve weeks). 
 
 
 
 
 
 
 
 
 
 
Figure 11. Untransfected FRTL-5 cells (plates 1-3) were grown in parallel with 
transfected cells (plates 4-9). 18 days after plates 4-9 were transfected (magnification 
100x). 
(A) FRTL-5 cells; (B) FRTL-5 + FugeneHD; (C) FRTL-5 cells + Blasticidin 
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Figure 12. FRTL-5 cells 18 days after cell transfection (magnification 100x) 
(A) CO plasmid cells; (B) CS plasmid cells; (C) insKD A, (D) insKD B, (E) insKD 
C, and (F) insKD D cells. (A-F) All cells received blasticidin.  
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Figure 13. FRTL-5 cells 24 days after cell transfection (magnification 100x) 
(A) CO plasmid cells; (B) CS plasmid cells; (C) insKD A, (D) insKD B, (E) insKD 
C, and (F) insKD D cells. (A-F) All cells received blasticidin.  
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Slower proliferation rates were observed in CO and CS vector cells (Table 1: 
plates 4 and 5) when compared to untransfected FRTL-5 cells (Table 1: plates 1 and 
2). This is most likely due to the effects of the selective blasticidin concentration 
present in the media (4μg/mL). After reducing the blasticidin concentration, CO and 
CS vector cells exhibited faster proliferation rates. CO and CS vector cells also 
exhibited faster growth rates than insKD construct cells. The observed slower growth 
rates in insKD construct cells are expected since FRTL-5 cells are thyroid cells. Under 
normal condition, these cells are stimulated to undergo proliferation in the presence of 
growth hormone, TSH, insulin and IGF-1. When FRTL-5 cells are successfully 
transfected with insKD constructs, they should show reduced cell proliferation in the 
presence of insulin and IGF-1. The differential growth rates in the different insKD 
constructs could be explained by the effectiveness with which each construct targets 
and decreases IR expression. This is a positive indication of successful transfection 
and decreased expression of IR. 
 
Discussion 
The results show that insKD constructs cause slower growth rates and 
morphological changes to the transfected cells. When blasticidin concentration was 
reduced to 2μg/mL from the initial selective concentration (4μg/mL), CO and CS vector 
controls exhibited faster growth rates than insKD transfected cells. Also, there were 
differential growth rates among the four insKD constructs. insKD C and D had faster 
growth rates than insKD A and B. Cells transfected with insKD A constructs had the 
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slowest growth rates. These results imply that transfection was successful and that the 
insKD plasmids successfully targeted the insulin receptor mRNA. The transfected cell 
lines that were obtained from this research will be used in future research.  
Morphological differences were also observed between non-transfected and 
transfected cells. FRTL-5 cells have polygonal morphology and proliferate as a 
monolayer. Transfected cells exhibited similar cell morphology to non-transfected 
cells but grew in isolated, spherical clumps. This observation was most apparent in 
cells with insKD constructs (figures 11 and 13).  
 By binding to IR or IGF-1R, insulin may induce cell proliferation and changes 
in metabolism. A common feature with T2DM is IR insensitivity. Decreased IR or 
IGF-1R activity may induce Porf-2 activity. Since Porf-2 has both anti-proliferative 
and pro-apoptotic properties, this decrease in activity might increase cell cycle arrest 
(figure 4).  
 
Insulin and IGF-1 Receptors in the Brain 
 Insulin and IGF-1 receptors have been shown to be expressed in the brain 
through in situ hybridization in rats. Studies show high levels of expression in granule 
cells, mitral cells, and glomerular layers of olfactory bulbs of the rat brain. Other 
studies show that IR mRNA is found in both cell bodies and synapses of hippocampal 
CA1 pyramidal cells, synapses of hypothalamic cells, and dendro-dendritic synapses 
of olfactory bulb cells. These results indicate that IR and IGF-1Rs are differentially 
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expressed in the brain and appear to be localized in specific regions involved with 
cognition, learning and memory (Williamson et al. 2012, Marks et al. 1990).  
 
Influence of T2DM on Cognitive Decline and Brain Volume 
 In a recent study, Espeland et al. (2013) measured regional brain volumes and 
ischemic lesion volumes in 1,366 women, aged 72-89 years, using magnetic resonance 
imaging (MRI). Measurements showed that women with T2DM had smaller total 
brain volumes and gray matter volumes, but not white matter volumes, compared to 
those without diabetes. These women also had significant increases in ischemic lesion 
volumes. The results suggest that diabetes has a negative effect on brain structure 
(Espeland et al. 2013). Similarly, a systematic review of observational studies by 
Cukierman et al. showed that a diagnosis of diabetes increased a person’s risk of 
cognitive decline and dementia (Cukierman et al. 2005). These results indicate that 
individuals with T2DM have increased risk of cognitive decline, dementia, and brain 
volume shrinkage.  
 
The Roles of RhoGTPases and RhoGAP in Cognition 
 
 RhoGTPases are a family of small G-proteins that cycle between an active 
GTP-bound and inactive GDP-bound forms. They have multiple intracellular 
functions, including stimulating microtubule stabilization, actin polymerization, and 
local protein translation. In the nervous system, RhoGTPase activity has shown to 
have effects on dendritic spine formation, synaptic plasticity and cognitive functions 
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(Linseman and Loucks 2008). Activation of RhoGTPases and downstream signaling 
altering actin turnover is important for dendritic spine changes. For example, RhoGAP 
activation (which decreases RhoGTPase activity) has been shown to decrease spine 
density and length.  
 Mutations that affect RhoGTPase associated proteins during pre- and neo-
natal development have a negative effect on neural connectivity, which may lead to 
impaired cognition and mental retardation (Newey et al. 2005). For example, 
mutations in ARHGEF6 (a RhoGEF), and WAVE-1 (a downstream protein), in adults 
led to a decrease in dendritic synapses, synaptic rearrangement, and learning 
impairments in mice (Kutsche et al. 2000 and Soderling et al. 2003). Also, 
oligophrenin-1 is a protein with a RhoGAP domain that is involved in X-linked mental 
retardation (Billuart et al. 1998). Porf-2 contains a RhoGAP domain and has been 
shown to have pro-apoptotic and anti-proliferative properties. Further research is 
needed to show whether increased expression of Porf-2 prolongs inactivation of 
RhoGTPase, which might lead to decreased reduction of spine density and cognitive 
impairment in both pre- and neo-natal development and adulthood. 
 
Conclusion 
 
Recent studies have shown that patients with T2DM are more likely to acquire 
neurodegenerative diseases, in particular Alzheimer’s disease, later in their lives. It is 
important to note that many of the neurodegenerative diseases are associated with 
brain shrinkage, most likely through increased neuronal cell death. Porf-2, which has 
anti-proliferative and pro-apoptotic properties, may contribute to the onset of neural 
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cell death when insulin/IGF-1 signaling is impaired. In this project, we have 
successfully obtained transfected insKD cell cultures that will be used for future 
research. Results show that cells transfected with an insKD construct exhibit slower 
proliferation rates than CO and CS vector controls. The transfected cells also exhibited 
different proliferation morphologies. Whereas FRTL-5 cells proliferate in a 
monolayer, transfected cells proliferate and accumulate in isolated clumps (figures 11 
and 13). By studying FRTL-5 insKD cells, it is our goal to provide an in vitro model 
of decreased IR/IGF-1R function, which may result in an increase of Porf-2 expression 
and subsequent cell death. By doing so, our research may provide greater insight into 
the mechanisms of how insulin resistance in T2DM leads to future cognitive 
impairment in the CNS.  
 
Future Directions 
 
 
Confirm IR and IGF-1R Knock-down Models 
 Further research is needed to confirm that the cell cultures obtained from this 
project are indeed IR knock-down FRTL-5 cell models. This can be achieved through 
Western blot, a technique used to measure protein expression levels. Similarly, IGF-
1R protein expression levels will be measured in FRTL-5 cells that were transfected 
with four different IGF-1R knock-down constructs obtained by Z. Wang. Successful 
IR or IGF-1R knock-down cells should have at least 60% lower IR or IGF-1R protein 
expression compared to non-transfected FRTL-5 cells. IR and IGF-1R mRNA 
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expression levels will be measured using qRT-PCR. Their expression is expected to be 
reduced by at least 60%.  
 
Porf-2 Expression in IR and IGF-1R Knock-down Cells  
Previous research on neural stem cells showed that Porf-2 exhibits both anti-
proliferative and pro-apoptotic properties (Ma and Nowak 2011). Porf-2 knock-down 
cells showed increased cell proliferation and underwent lower rates of apoptosis when 
presented with pro-apoptic compounds such as bleomycin or STS. Also, in the 
presence of IGF-1, it was shown that Porf-2 mRNA expression decreased. These 
results imply that Porf-2 is downstream of insulin and IGF-1 in signal transduction. 
Porf-2 mRNA expression using qRT-PCR technique should be measured in IR and 
IGF-1R knock-down FRTL-5 cells to test this hypothesis.  
 
Porf-2 Knock-out Mice 
The broader goal for this research project is to eventually develop a strategy to 
combat cognitive decline in T2DM patients. If we can establish that reduced insulin 
signaling causes increased Porf-2 protein expression, we will have shown that there is 
a critical link between neurodegenerative pathways and T2DM. Furthermore, the aim 
is to apply the results from this preliminary study to animal models such as Porf-2 
knock-out transgenic mice. We do not know if knock-out (KO) mice will exhibit 
normal pro-apoptotic and anti-proliferative properties in the CNS. The expected 
outcome is that a lack of Porf-2 expression in KO mice will decrease 
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neurodegeneration in T2DM. If this is indeed the case, manipulating Porf-2 expression 
may lead to development of a therapeutic method to treat T2DM patients who are at 
risk of developing cognitive decline.  
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